Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Healthy Community Project

- PMLiVE

Sanofi launches a monster mobile diabetes game

Monster Manor iPhone and Android apps aim to encourage better management of the condition

Sanofi reception

Sanofi and Regeneron’s cholesterol antibody aces phase III trial

Results confirm companies' lead over Amgen, Pfzer, Roche and Novartis

Sanofi reception

Nasacort approval cements Sanofi’s OTC ambitions

Can sell allergy spray directly to consumers in US

- PMLiVE

Third try for MannKind’s inhaled insulin

Pharma company resubmits regulatory filing for diabetes treatment Afrezza in the US

- PMLiVE

Lilly enters cancer collaboration in China

Signs deal with Chi-Med to develop and commercialise fruquintinib

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

EASD 2013: Novo Nordisk’s diabetes combination IDegLira impresses in study

Mix of Tresiba and Victoza helps 81 per cent achieve blood sugar target in phase III

Sanofi reception

EASD 2013: Sanofi prepared for biosimilar threat to Lantus

Next generation insulin U300 set to launch at time of patent expiration

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

- PMLiVE

Boehringer launches integrated Hispanic diabetes campaign

Creative development overseen Miami-based agency Republica

Unravelling China’s healthcare sector

How will health reforms, the tightening of regulations and the emergence of a domestic drug industry impact global pharmaceutical companies?

- PMLiVE

GSK’s Chinese sales hit by scandal, say analysts

Company estimated to have lost a third of its revenues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links